Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

Molecular Medicine Reports

Volumn 11, Issue 6, 2015, Pages 4508-4512

  Tang, Ming Rui ^a   Wang, Yu Xin ^a   Guo, Shu ^a   Han, Si Yuan ^a   Li, He Huan ^a   Jin, Shi Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Melanoma; Metastasis; Plasma; Prognosis; Transforming growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHLOROGENIC ACID; CYCLIN D1; ENDOGLIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; THY 1 ANTIGEN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BRDU ASSAY; CASE REPORT; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UP-REGULATION;

EID: 84924690294     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3250     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Diffey BL: The future incidence of cutaneous melanoma within the UK. Br J Dermatol 151: 868-872, 2004.
3. Sousa JF, Torrieri R, Silva RR, et al: Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One 5: e13510, 2010.
4. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178, 2000.
5. Derynck R and Zhang YE: Smad-dependent and Smad independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003.
6. Wu MY and Hill CS: Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 16: 329-343, 2009.
7. Roberts AB and Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623, 2003.
8. Busse A and Keilholz U: Role of TGF in melanoma. Curr Pharm Biotechnol 12: 2165-2175, 2011.
9. Lasfar A and Cohen-Solal KA: Resistance to transforming growth factor mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis 31: 1710-1717, 2010.
10. Malaponte G, Zacchia A, Bevelacqua Y, et al: Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep 24: 81-87, 2010.
11. Goel MK, Khanna P and Kishore J: Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 1: 274-278. 2010.
12. Massagué J: TGFbeta in Cancer. Cell 134: 215-230, 2008.
13. Leivonen SK and Kähäri VM: Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 121: 2119-2124, 2007.
14. Albino AP, Davis BM and Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 51: 4815-4820, 1991.
15. Bursch W, Oberhammer F and Schulte-Hermann R: Cell death and its protective role in disease. Trends Pharmacol Sci 13: 245-251, 1992.
16. Schmid P, Itin P and Rufli T: In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16: 1499-1503, 1995.
17. Van Belle P, Rodeck U, Nuamah I, Halpern AC and Elder DE: Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148: 1887-1894, 1996.
18. Rodeck U, Bossler A, Graeven U, et al: Transforming growth factor b production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54: 575-581, 1994.
19. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-b1 and TGF-b2 in patients with disseminated malignant melanoma. Br J Cancer 77: 1492-1494, 1998.